Clinical Data Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test BioPharma DiveThe results support Takeda s long-held belief in zasocitinib s superiority and could help it gain a commercial advantage over Bristol s therapy.Immunology & InflammationRead full story pharminent June 11, 2026 (Last updated: June 11, 2026) BioPharma Dive The results support Takeda s long-held belief in zasocitinib s superiority and could help it gain a commercial advantage over Bristol s therapy. Immunology & Inflammation Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Beren pockets $300m to take Niemann-Pick disease therapy to marketNext: SonoThera bags $125M series B to advance safer gene therapies Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
